Astellas Gene Therapies
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Gene Therapies sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Astellas Gene Therapies: 7 sponsored US clinical trials, 2 recruiting.
Astellas Gene Therapies sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Myotubular Myopathy, with 3 trials.
Upper-quartile sponsor footprint
Astellas Gene Therapies sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
NCT07052929
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
NCT06581146
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820
Gene Transfer Study in Patients With Late Onset Pompe Disease
NCT04174105
A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)
NCT03199469
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects
NCT02704273
A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)
NCT02231697
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Astellas Gene Therapies pipeline
2 recruiting of 7 indexed (29% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: X-Linked Myotubular Myopathy (3 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Gene Therapies: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Astellas Gene Therapies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Astellas Gene Therapies page
7 registered trials is a research-attention snapshot, not an endorsement of Astellas Gene Therapies or any single study.
- 2 of Astellas Gene Therapies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- X-Linked Myotubular Myopathy is the condition Astellas Gene Therapies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Myotubular Myopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Astellas Gene Therapies pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.